Stock 6622 ZHAOKE OPHTHALMOLOGY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhaoke Ophthalmology Limited

Equities

6622

KYG989M51017

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:07 2024-06-03 EDT 		5-day change 1st Jan Change
1.49 HKD -0.67% Intraday chart for Zhaoke Ophthalmology Limited +0.68% -62.28%
04-29 Zhaoke Ophthalmology Shrinks Loss in 2023 MT
04-08 Zhaoke Ophthalmology Limited Announces the Resignation of Chen Yu Has as Non-Executive Director CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHAOKE OPHTHALMOLOGY LIMITED Stock Zhaoke Ophthalmology Limited
-62.28% 105M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+42.94% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.34% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.90% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.40% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.50% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.47% 240B
B+
NOVARTIS AG Stock Novartis AG
+9.26% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.07% 206B
A+
AMGEN INC. Stock Amgen Inc.
+5.95% 164B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 6622 Stock
  4. Ratings Zhaoke Ophthalmology Limited